WHO ARE BIOCURE'S INVESTORS?
WHERE DOES BIOCURE STAND TODAY?
WHO ARE BIOCURE'S MANAGEMENT?
WHO ARE BIOCURE'S SCIENTIFIC ADVISORY BOARD?
WHO IS ON BIOCURE'S BOARD OF DIRECTORS?

Who are BioCure's Investors?

Our first round of investment, completed in September 1999, was made by the original supporters of the seed project within CIBA Vision:

:::	CIBA Vision, Switzerland and USA
:::	Novartis Venture Fund, Switzerland
:::	CRCERT/CSIRO, Australia
:::	Institute for Eye Research, Australia

Where does BioCure stand today?

BioCure continues to reinvest its financial returns from its license to and its manufacturing collaboration with Biocompatibles UK Ltd.

By restricting its focus to R&D and manufacturing, BioCure has been able to continue to partner with leading commercial and research partners in the therapeutic areas of spine and orthopedic and woundcare. These programs target short and medium-term regulatory approvals.

We are seeking to expand collaborations in these sectors.

Additionally, we have recently formed a Swiss subsidiary company, BioCure (Schweiz) GmBH, which is focused on the development of our intellectual capital in the exciting area of nanotechnology. We are actively seeking new collaborations and, potentially, new investors as we develop a detailed product pipeline.

Who are BioCure's management?

We have an experienced management team supported by highly trained and innovative researchers in the areas of polymer science, cell biology, engineering, manufacturing and quality control.

Dr. Adrian Hunter is the CEO, President and co-Founder of BioCure. He has more than 32 years experience in the healthcare field, mostly in senior management positions. His experience spans operations, finance, marketing and R&D. He proposed and negotiated the spin-off of BioCure from Novartis.

On leaving University in 1969, he joined Scientific Control Systems, Ltd. as a consultant. In 1973 he joined CIBA-Geigy (UK), Ltd. - now part of the Novartis Group - as Head of Mathematics, Statistics, and Computing. He then held several positions within the Pharmaceutical Division - P.A. to the Managing Director in the UK, Product Manager and Financial Analyst in Switzerland, returning to the UK as Director (VP) of Business Development and member of the Pharmaceutical Management Committee. In the latter position he set up CIBA Consumer Pharmaceuticals in the UK.

In 1985, he joined Titmus Eurocon (a member of the CIBA Vision Group) in Germany, responsible for CIBA Vision's world-wide (ex. USA) marketing and sales. He joined the world-wide Management Committee of CIBA Vision as Director (VP) of Finance in 1987 and later served as the Head of European Operations. In 1991, he became Group Vice President with world-wide responsibilities for R&D and marketing, based initially in Switzerland, and from 1993, in Atlanta.

During his time with CIBA Vision, he was responsible for successfully negotiating several acquisitions and other important contracts. He was heavily involved in the development and implementation of CIBA Vision's long-term strategy. He has a specific interest in breakthrough projects and process innovation and the organization and management of multi-disciplined teams. He managed two major breakthrough projects at CIBA Vision. This led to the introduction of the world's first true extended wear soft contact lens, Night & Day, and to the Dailies disposable contact lens - CIBA Vision's most successful product to date - based on a novel, low cost, contact lens manufacturing process.

Dr. Hunter is a graduate of London University in Mathematics and Physics (1st class honors), with a Ph.D. in Theoretical Physics. He also has a Certified Diploma in Accounting and Finance.

Mr. Andrew Maslaveckas is Co-Founder and Chief Operating Officer of BioCure responsible for all of BioCure’s research and commercial operations. Mr. Maslaveckas has over 28 years of experience in managing and building both consumer and professional health care companies.

Prior to the establishment of BioCure, Mr. Maslaveckas, as Head of New Growth Businesses at CIBA Vision, was primarily responsible for identifying the commercial and market rationale for BioCure's spin-off from Novartis.

Joining Ciba Vision in 1993, Mr. Maslaveckas, as Global Head of Contact Lenses, was charged with developing and implementing an aggressive strategy to build a significant presence in the disposable contact lens segment and to grow CIBA Vision's contact lens profitability and market share in the contact lens business in the face of strong competition from Johnson & Johnson and Bausch & Lomb. During his tenure, CIBA Vision's sales revenues increased over 30% per annum and approached $500 million with excellent returns on sales and capital.

Prior to 1993, Mr. Maslaveckas worked for 14 years with Johnson & Johnson in a number of executive positions in the consumer and professional businesses.

In 1989, he joined Vistakon UK in its first year as Managing Director responsible for relaunching its ACUVUE* disposable contact lens franchise following initial revenue and financial disappointments. Mr. Maslaveckas initiated a highly successful campaign which culminated in Vistakon achieving the #1 position in the market in his second year and building the business to J&J's largest revenue brand in the UK through aggressive consumer and professional initiatives. In 1991, Mr. Maslaveckas added responsibilities for Vistakon Germany and later joined both the J&J UK Board and was Vistakon's representative on the European Management Committee of J&J's Professional segment.

In 1985, Mr. Maslaveckas, following a regional assignment in Morocco, was named as the first Managing Director of the company and charged with the establishment of a sales, marketing and manufacturing presence and infrastructure. During his six years in Morocco, the company became the #1 market leader in the baby toiletries, sanitary protection and shampoo markets through aggressive and innovative commercial programs. Latterly, the company assumed responsibilities for J&J's professional and pharmaceutical franchises.

Mr. Maslaveckas joined J&J in the UK as an Area Manager and subsequently a Regional Manager in its sales and marketing department charged with P&L responsibility for distributor territories in Southern Europe, Africa and the Middle East.

Mr. Maslaveckas graduated M.A. (Hons) in French and Russian from the University of Glasgow in 1977.

Dr. Dennis Goupil is the Chief Technical Officer and Vice President of Research and Development. He brings over 25 years experience in medical research and product development, including 15 years at the Director / Vice President level. In total, Dr. Goupil has directed the product development of over 20 commercial products. Throughout his career, Dr. Goupil has also had responsibilities for managing intellectual property, conducting clinical trials, technical assessments for mergers and acquisitions, and leading the technical team in transferring new businesses obtained through acquisition.

Dr. Goupil started his research career in medical devices as part of the team that developed the total artificial heart in the 1970s. His responsibilities included conducting interfacial studies at the polymer-blood interface that led to the choice of materials for the artificial heart. Following this research, Dr. Goupil was responsible for the development of a surface chemistry laboratory in central R&D for American Cyanamid where his team conducted research on medical devices and pharmaceutical products. He then joined American Cyanamid's Davis & Geck division with responsibilities for developing new product opportunities for degradable polymers. This research was conducted during the pioneering days of degradable polymers and led Dr. Goupil into tissue engineering and degradable devices in orthopaedics (pins, screws, plates), plastic surgery (nerve regeneration tubes), vascular surgery (small diameter grafts, vessel clamp), and general surgery (bowel anastomosis rings, staples). In this role, Dr. Goupil was also responsible for managing the intellectual property for Davis & Geck.

Following Davis & Geck, Dr. Goupil joined Cytotherapeutics where he led the product development and scale-up of a novel cellular-based implant that was focused on treating neurological diseases such as Parkinson's disease. He later joined Pharmacia Ophthalmics as Vice-President of R&D for intraocular lens and medical device product development. Following relocation back to the northeast for personal reasons, Dr. Goupil was Vice-President of R&D for Datascope's Cardiac Assist Division where he directed the development of new intra-aortic balloons and in the establishment of a clinical trial to evaluate the use of immediate IAB therapy for heart attack patients. Lastly, just prior to joining BioCure, Dr. Goupil was responsible for biomaterials and surgical product development for the Meditech division of Boston Scientific. In this role, he developed and commercialized vascular grafts and fabrics used by the vascular surgeon. He also led the technical evaluation of several potential acquisitions and license agreements, including the management of the transfer of technology and staff associated with acquired companies.

Dr. Goupil holds a Ph.D. in Physical Chemistry from Clarkson College of Technology, a M.S. in engineering from the University of Cincinnati, a B.S. in chemistry from Niagara University.

Dr. Thomas Hirt is Vice President of Research and Development and General Manager of BioCure (Schweiz) GmBH.

Dr. Hirt joined Ciba Geigy AG in 1995 working at its Central Research Unit in Basel, Switzerland. After one year, he transferred to Ciba Vision in Atlanta, USA as a Senior Scientist working primarily on developing new polymeric materials for extended wear contact lenses. In this context, he also synthesized amphiphilic triblock copolymers, that were used to make the first hollow, polymeric nanovesicles in water.

After 3 years at Ciba Vision, he moved back to Switzerland to head up the Research and Development and New Business Development efforts at SEFAR, Printing Division. During the 8 years at SEFAR AG, as a member of the Divisional Management, he implemented state of the art R&D procedures, increased sales of new products from annual growth in the low single digits to high double digits percentages. At SEFAR, he gained experience in contract negotiations, business processes, product development and project and technology management.

Dr. Hirt joined BioCure in January 2007 to lead the start-up of BioCure Switzerland whose primary focus is on nanotechnology. As an original inventor, he is responsible for the business and product development of the hollow, polymeric nanovesicles. He is also responsible for the corporate materials development group.

Dr. Hirt is a graduate from ETH in Zurich in Technical Chemistry, conducted his PhD in polymer science and holds a Diploma in Marketing. The subject of his PhD is the synthesis and characterization of new degradable polymers for medical applications.

Who are BioCure's Scientific Advisory Board?

:::	Professor Jennifer West, Ph.D., Rice University
:::	Michael K. Schaufele, The Emory Clinic

Who is on BioCure's Board of Directors?

:::	Tariq Aziz , CIBA Vision
:::	Ruedi Gygax, Novartis Venture Fund
:::	Brien Holden, CRCERT
:::	Adrian Hunter, BioCure

Please contact us if you have any questions. We'd be happy to provide you with more information.